XORTX Therapeutics Statistics
Total Valuation
XRTX has a market cap or net worth of $2.46 million. The enterprise value is $1.64 million.
Important Dates
The next estimated earnings date is Friday, March 20, 2026, before market open.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XRTX has 6.54 million shares outstanding. The number of shares has increased by 53.07% in one year.
| Current Share Class | 6.96M |
| Shares Outstanding | 6.54M |
| Shares Change (YoY) | +53.07% |
| Shares Change (QoQ) | +28.20% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 5.87% |
| Float | 6.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.11 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.00% and return on invested capital (ROIC) is -57.75%.
| Return on Equity (ROE) | -98.00% |
| Return on Assets (ROA) | -46.84% |
| Return on Invested Capital (ROIC) | -57.75% |
| Return on Capital Employed (ROCE) | -121.85% |
| Weighted Average Cost of Capital (WACC) | 5.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$885,435 |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.13% in the last 52 weeks. The beta is 0.15, so XRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -57.13% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 41.29 |
| Average Volume (20 Days) | 220,386 |
Short Selling Information
The latest short interest is 107,400, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 107,400 |
| Short Previous Month | 2,008 |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.72% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.54M |
| Pretax Income | -2.66M |
| Net Income | -2.66M |
| EBITDA | -2.43M |
| EBIT | -2.54M |
| Earnings Per Share (EPS) | -$0.56 |
Full Income StatementBalance Sheet
The company has $864,514 in cash and $37,287 in debt, with a net cash position of $827,227 or $0.13 per share.
| Cash & Cash Equivalents | 864,514 |
| Total Debt | 37,287 |
| Net Cash | 827,227 |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 2.08M |
| Book Value Per Share | 0.32 |
| Working Capital | 662,027 |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.95M |
| FCF Per Share | -$0.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
